Sumary of Dexpramipexole reduces eosinophils, improves lung function in moderate to severe asthma:
- Presented at: European Respiratory Society International Congress;
- Back to Healio In patients with moderate to severe eosinophilic asthma, treatment with dexpramipexole depleted blood and tissue eosinophils, which correlated with improvement in lung function, according to results of the phase 2 EXHALE trial.
- “The development of the drug then pivoted to development in eosinophil-mediated immune diseases.
- Two-thirds of participants were on moderate- or high-dose inhaled corticosteroid and long-acting beta agonist therapy and 20% to 30% met criteria for severe asthma.
- The primary outcome was change in blood eosinophil count from baseline to 12 weeks.
- At 12 weeks, researchers observed dose-dependent blood eosinophil attenuation among participants assigned dexpramipexole.
- This reaction was equivalent to an 80% reduction in eosinophil count with the 300 mg dexpramipexole dose compared with placebo (P <
- “The drug lowers eosinophils over an 8- to 12-week period, supporting its impact on the bone marrow and eosinophil maturation across all three tracing strata and subsequent recovery on drug withdrawal over a further 12 weeks,” Siddiqui said.